Analyst Price Target is $11.00
▲ +165.06% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Marker Therapeutics in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 165.06% upside from the last price of $4.15.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Marker Therapeutics. This Buy consensus rating has held steady for over two years.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.
Read More